Literature DB >> 19586591

Assessment of neuropathic pain in cancer patients.

Deborah T Blumenthal1.   

Abstract

Neuropathic pain is an increasingly common problem facing the cancer patient. Painful neuropathy can come from various sources and significantly impact quality of life. The most commonly observed scenario is paraesthesia and dysesthesia as a result of toxic effects of chemotherapies on the distal peripheral nerves. Neuropathic pain should be addressed ideally with the help of a neuro-oncologist, and it usually can be successfully treated with a variety of agents, including atypical analgesics such as antidepressants, newer drugs with analgesic benefit, and opioids for more refractory cases. Direct and indirect effects of the primary neoplasm need to be considered in the etiology of specific syndromes of mononeuropathies and plexopathies.

Entities:  

Mesh:

Year:  2009        PMID: 19586591     DOI: 10.1007/s11916-009-0045-6

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  31 in total

1.  Electrophysiological evaluation of visual pathways in paclitaxel-treated patients.

Authors:  V Scaioli; A Caraceni; C Martini; S Curzi; G Capri; G Luca
Journal:  J Neurooncol       Date:  2005-08-25       Impact factor: 4.130

Review 2.  Cytarabine and neurologic toxicity.

Authors:  W J Baker; G L Royer; R B Weiss
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

Review 3.  Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.

Authors:  Sherry Wolf; Debra Barton; Lisa Kottschade; Axel Grothey; Charles Loprinzi
Journal:  Eur J Cancer       Date:  2008-06-18       Impact factor: 9.162

4.  Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study.

Authors:  M D Stubblefield; L T Vahdat; C M Balmaceda; A B Troxel; C S Hesdorffer; C L Gooch
Journal:  Clin Oncol (R Coll Radiol)       Date:  2005-06       Impact factor: 4.126

5.  Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.

Authors:  R G van der Hoop; M E van der Burg; W W ten Bokkel Huinink; C van Houwelingen; J P Neijt
Journal:  Cancer       Date:  1990-10-15       Impact factor: 6.860

6.  Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy.

Authors:  G Hildebrandt; E Holler; M Woenkhaus; G Quarch; A Reichle; B Schalke; R Andreesen
Journal:  Ann Oncol       Date:  2000-06       Impact factor: 32.976

7.  Peripheral neuropathy associated with capecitabine.

Authors:  M Wasif Saif; Tina E Wood; Philip J McGee; Robert B Diasio
Journal:  Anticancer Drugs       Date:  2004-09       Impact factor: 2.248

Review 8.  Antiepileptic drugs: indications other than epilepsy.

Authors:  Edoardo Spina; Giulio Perugi
Journal:  Epileptic Disord       Date:  2004-06       Impact factor: 1.819

9.  Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells.

Authors:  Hai Wei Jin; Sarah J L Flatters; Wen Hua Xiao; Howard L Mulhern; Gary J Bennett
Journal:  Exp Neurol       Date:  2007-11-17       Impact factor: 5.330

10.  Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.

Authors:  Laurence Gamelin; Michele Boisdron-Celle; Remy Delva; Véronique Guérin-Meyer; Norbert Ifrah; Alain Morel; Erick Gamelin
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

View more
  2 in total

1.  Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer.

Authors:  Ryo Otsuka; Satoru Iwasa; Takako Yanai; Hidekazu Hirano; Hirokazu Shoji; Yoshitaka Honma; Natsuko Okita; Atsuo Takashima; Ken Kato; Hironobu Hashimoto; Masatoshi Sekiguchi; Yoshinori Makino; Narikazu Boku; Masakazu Yamaguchi
Journal:  Int J Clin Oncol       Date:  2019-12-18       Impact factor: 3.402

2.  Elevation of tumor necrosis factor α in dorsal root ganglia and spinal cord is associated with neuroimmune modulation of pain in an animal model of multiple sclerosis.

Authors:  F Begum; W Zhu; C Cortes; B MacNeil; M Namaka
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-14       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.